Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

inclisiran (Leqvio)

Therapeutic Area: Primary hypercholesterolemia
Draft recommendations posted for stakeholder feedback: July 18, 2024
End of feedback period: August 01, 2024
Draft Recommendation

Submit Feedback

etrasimod (Velsipity)

Therapeutic Area: Ulcerative colitis
Draft recommendations posted for stakeholder feedback: July 18, 2024
End of feedback period: August 01, 2024
Draft Recommendation

Submit Feedback

lebrikizumab (Ebglyss)

Therapeutic Area: atopic dermatitis
Draft recommendations posted for stakeholder feedback: July 18, 2024
End of feedback period: August 01, 2024
Draft Recommendation

Submit Feedback

cabotegravir (Apretude)

Therapeutic Area: HIV-1 infection, pre-exposure prophylaxis
Draft recommendations posted for stakeholder feedback: July 18, 2024
End of feedback period: August 01, 2024
Draft Recommendation

Submit Feedback

cariprazine (Vraylar)

Therapeutic Area: Schizophrenia
Draft recommendations posted for stakeholder feedback: July 18, 2024
End of feedback period: August 01, 2024
Draft Recommendation

Submit Feedback

remdesivir (Veklury)

Therapeutic Area: COVID-19 in hospitalized patients
Draft recommendations posted for stakeholder feedback: July 18, 2024
End of feedback period: August 01, 2024
Draft Recommendation

Submit Feedback

remdesivir (Veklury)

Therapeutic Area: COVID-19 in non-hospitalized patients
Draft recommendations posted for stakeholder feedback: July 18, 2024
End of feedback period: August 01, 2024
Draft Recommendation

Submit Feedback

Open Calls for Patient and Clinician Input